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Abstract
Introduction: Benign prostatic hyperplasia (BPH) is a disease of the prostate commonly seen in elderly 
males known to cause lower urinary tract symptoms (LUTS) that may require surgery as a part of 
treatment. Transurethral resection of the prostate (TURP) is considered the gold standard of surgical 
treatment, but it is not without complications. Laser photoselective vaporisation of the prostate 
(PVP), introduced in 1998 as an 80 W Nd:YAG laser which passed through a KTP (potassium-titanyl-
phosphate) crystal, emerged as a safe alternative to TURP in selected cases. A recent upgrade to the 
Greenlight XPS 180 W powered with an LBO (lithium triborate) crystal has been available for use since 
2012. Data on the use of this new upgrade is still being collected and analysed, especially in patients 
with large prostates or high risk cases. We analysed cases done at Jaslok Hospital over a 2-year period. 
Methods: A total of 34 patients who underwent Laser PVP using XPS 180W for LUTS due to BPH 
at Jaslok Hospital were part of this study. We analysed the pre- and postoperative variables and the 
intraoperative parameters of all patients. 
Results: The XPS 180W was found to be safe and efficacious. Eighteen patients were high-risk cases, 
classified as ASA (American Society of Anesthesiologists) Classes 3 and 4. Average postoperative 
catheter duration was 40.18 hours. In prostates of size <80 mL, an average of 229 kJ of energy was 
used. In large prostates (>80 mL), an average of 390 kJ of energy was used. No major complications 
were seen in any of the high-risk patients, classified as Clavien Dindo Class 3 and 4. The postoperative 
drop in IPSS (International Prostate Symptom Score) was 8.7.
Conclusion: We found that Green Light Laser XPS 180W may be used for large (>80 g) prostates, 
hitherto an indication for open surgery, and that it may be used in high-risk patients, who were 
otherwise unfit for TURP. It is safe and efficacious. Further, multicenter trials are required to confirm 
the findings. 
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Introduction 
Benign prostatic hyperplasia (BPH) is a commonly seen 
problem of adult males, characterised by bladder outlet 
obstruction and varying degrees of lower urinary tract 
symptoms (LUTS).1 Open prostatectomy (OP) for large 
glands (>80 mL) is considered for treatment of patients in 
whom medical therapy has failed to alleviate symptoms of 
BPH.2 For smaller glands (>30 mL-80 mL) in patients in 
whom medical therapy has failed, transurethral resection 
of the prostate (TURP) is recommended. However, TURP 
is not without complications. A recent review of over 
10000 patients showed complications of TURP include 
failure to void (4.5%-5.8%), repeat surgery (1.1% to 5.6%), 
infection of the urinary tract (3.6%-4.2%), bleeding 
requiring blood transfusions (2.0% to 2.9%) and TUR 
syndrome (0.8%-1.4%). In this series, the mortality rate 
was 0.10% and the short-term morbidity rate was 11.1%.3 
In elderly patients on anticoagulant medication and 
antiplatelet drugs, the risk of TURP-related hemorrhage 
increases, necessitating the use of alternative sources of 
energy for BPH.4
The first study on photoselective vaporisation of the 
prostate (PVP) involving the GreenLightTM KTP laser 
was published in 1998 by Malek et al.5 GreenLightTM laser 
emits radiation at a wavelength of 532 nm. It is selectively 
absorbed in tissue by haemoglobin (‘red’ in colour), and 
has a penetration depth of 0.8 mm. The tissue target 
chromophore is the haemoglobin molecule, and the laser 
is delivered using a side-firing, silica-based, fibre through 
a special visual ‘scope.’ PVP has been extensively studied 
with incrementally improved systems, the GreenLightTM 
HPS 120W system and in 2010, the GreenLightTM XPS 
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180W systems (Boston Scientific, Marlborough, MA, 
USA). In the improvement of the XPS 180W system, 
there was 50% increase in power, and a 50% increase 
in the laser beam, diameter, which kept power density 
the same as before6. Also added on were liquid cooling 
(with normal saline) of the fibre, an automatic system to 
shut down power with overheating of the fibre, and new 
coagulation settings that provided a pulsed as opposed 
to quasi-continuous low power mode.7 PVP has been 
used in patients taking oral anticoagulant medications 
and found to be safe.8,9 The mechanism of PVP relies on 
its photoselective absorption of oxyhemoglobin in the 
prostate, causing ‘photovaporization’ of the tissue of the 
prostate, reducing intra-operative bleeding.10
Methods
Study Population
Thirty-four patients, who were diagnosed with LUTS 
due to BPH, were operated upon using the GL-XPS 
system. One of 4 experienced surgeons performed all the 
procedures, done between July 2013 and June 2015. All 
data was collected and recorded prospectively. 
Surgery indications were based on criteria set by the 
American Urological Association11 and the European 
Association of Urology.2 The baseline parameters and 
surgery outcomes were collected (Tables 1 and 2). 
Patients on anticoagulant medication and those who 
were catheterized before surgery or had a history of 
urinary retention were also included. Patients on aspirin 
(acetylsalicylic acid) were asked to continue taking 
the medication. We excluded patients with bladder 
neck stenosis or urethral stricture, suspected prostatic 
malignancy, bladder tumours, neurogenic bladder.
The surgical procedures were performed as per the steps 
given by International GreenLight™ Users group.12 
GreenLight™ XPS was used throughout the procedure, 
and pure vaporization was used. The irrigant was room 
temperature normal saline which was used in a 24F laser 
cystoscope. The highest power setting reached was 180W, 
adjusted in 10W steps.
Assessment
Standard parameters related to prostate surgery and 
complications of surgery and symptoms of patients 
were assessed prospectively, and one month after the 
surgery. In the preoperative assessment, prostate volume 
(mL), International Prostate Symptom Score (IPSS), 
and maximum urinary flow rate (Qmax, mL/s) were 
measured. The preoperative assessments also included 
physical examination, and medical history, urine analysis 
and renal function tests, a serum prostate-specific antigen 
level (PSA, ng/mL), and serum electrolytes. Patients with 
suspicious DRE’s and/or high PSA levels were further 
evaluated for carcinoma of the prostate (CaP) prior to 
subjecting them to GreenLightTM Laser PVP, in the form 
of biopsy. The intraoperative readings recorded were total 
lasing time (min), total energy usage (kJ), as well as total 
operating time (min), measured from start of cystoscopy 
to insertion of catheter. 
Statistical Analysis
Statistical analysis was performed using the Google 
Sheets online software. For numerical data, independent 
t tests were performed. To compare two sets of before and 
after surgery data, a paired t test was used. Categorical 
data was analysed using the chi-square test. We took a P 
value of <0.05 as statistically significant. Statistical results 
were shown as mean with standard deviation (SD) as a 
percentage of total patients.
Number of Patients
A total of 37 patients underwent the GreenLightTM Laser 
PVP at Jaslok Hospital between May 2013 and May 2015. 
Three patients were excluded from the study because of 
suspected carcinoma. The average age was 68.74 years. 
There was one Arab patient, the rest were of Indian 
ethnicity. 
Table 1. Patient Characteristics
Age, years (range) 68.74 (53–87)
PSA, ng/dL (range) 2.51 (0.6–6.15, SD = 1.39)
Prostate volume, mL (range) 57.1 (10–162, SD = 35.46)
Post-void residue (PVR), mL (range) 137.8 (0–916, SD = 201.1)
Operating time, min (range) 87 (60–240, SD = 32.4)
Lasing time, min (range) 44.23 (25–130, SD = 18.62)
Applied energy, kJ (range) 267 (171–800, SD = 109)
IPSS pre-operative score (range) 20.0 (15–25, SD = 2.81)
Table 2. Characteristics of Patients
Number (n) 34
Average IPSS 20 (15-25, SD = 2.81)
History of retention 9/34 (24%)
Catheterised on admission 9/34 (24%)
Duration of catheterisation (days) 29 (2-100, SD = 20.57)
Urinary tract infection 5/34 (16%)
Diabetes 9/34 (26%)
Heart disease 13/34 (38%)
Hypertension 16/34 (47%)
Antiplatelet medication 14/34 (41%)
Aspirin (acetylsalicylic acid) 14/34 (41%)
Clopidogrel 11/34 (31%)
H/o TURP 3/34 (9%)
Bladder wall thickness (mm) 4.5 
ASA Class III & IV 18 (54%)
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Symptoms
Patients presented due to LUTS. They were evaluated 
using the IPSS score. The average IPSS score was 20, range 
15-25. A total of 9 patients had a history of retention of 
urine. The average number of episodes of retention was 
1.55. Nine patients were catheterised on admission. 
History of Surgeries
Fifteen patients (44%) had undergone some type of 
surgery. Pertinently, 3 (9%) had undergone TURP in the 
past. 
Admission Status
Two (6%) patients were referred to the Urology Department 
from Intensive Care (ICU) for their symptoms. The rest 
were scheduled admissions for planned procedures. 
Examination Findings
The 2 patients referred from ICU were unstable; one of 
them required continuous oxygen and had a poor left 
ventricular function of 15%. The other had undergone 
an angioplasty recently and was on vasopressor support 
for stabilisation. The rest of the patients were stable on 
admission. 
None of the patients had a palpable bladder on 
examination in hospital. The DRE findings of patients 
in this study were not suspicious for malignancy. A total 
of 4 patients (12%) had Grade I prostatomegaly (Upper 
border of prostate easily reached), 26 (76%) had Grade 
II prostatomegaly (Upper border reached with difficulty) 
and 4 (12%) had Grade III prostatomegaly (Upper border 
not reached) 
Investigations
The haemoglobin (Hb) levels for the patients ranged from 
8 g/dL to 17 g/dL, with an average of 12.78 g/dL. Four 
patients (12%) had Hb levels of <10 g/dL. The average 
packed cell volume (PCV) was 38.8 (Range 25-50). The 
average platelet count was 252 000/dL (Range 150 000-
450 000). Serum creatinine levels averaged 1.14 mg/dL, 
with a range of 0.7 mg/dL-2.7 mg/dL.
PSA Levels
The average PSA levels were 2.5, with a range of 0.5-6.15 
ng/dL. Four (12%) of patients had a PSA level of >4.0. 
One patient with a PSA of 6.15 had a history of UTI at 
the time of measurement, and tissue taken during the 
procedure was negative for malignancy. One patient (PSA 
of 5.3) had undergone a TRUS guided biopsy which was 
negative, and the other two had reasonably large glands of 
sizes 130 g (PSA of 4.5), and 87 g (PSA of 5.9) respectively 
to offset the relatively high PSA level.
Prostate Size
The average size of the prostate was 57.0 g, with a range 
from 10-162 g. Eight patients (24%) had prostates 
of >80 g size. 
Post-void Residue and Bladder Findings
The average post-void residue (PVR) was 137.8 mL 
(Range from 0-916 mL). Seventeen patients (50%) had 
PVR of over 75 mL. No patient had bladder diverticuli, 
and the average documented bladder wall thickness was 
4.5 mm (range 3.5 - 6.0 mm) 
Surgery Characteristics
Duration of Surgery
The average duration of surgery was 1.27 hours, or 76 
minutes, including anaesthesia time. The range was from 
1 hour to 4 hours. 
Energy Used 
The average energy used across all cases was 267.2 kJ per 
case. In cases where the size of the prostate was >80 g 
(n=8), the energy used averaged 390 kJ per case. 
Fibres Used
The advantage of having the 180W XPS system remains 
the ability to deliver high amounts of energy in low 
periods of time with reliability. We used 1.02 fibres per 
case, with only one (3%) of cases requiring more than one 
fibre. 
Lasing Time
The average lasing time was 44.2 minutes per case, with a 
range from 25-130 minutes. 
Postoperative Characteristics
In all patients, there was mild haematuria postoperatively. 
In 5 patients (15%) irrigation had to continue more than 24 
hours. Four (80%) of these patients were anticoagulated. 
Seven patients (21%) had their catheters removed on day 
1, and 22 patients (64%) were still catheterised after 24 
hours, but without any irrigation, and the urine was clear 
(Table 3). 
Catheter Removal
The average duration of catheterisation was 1.91 days, 
or 40.17 hours. Seven (21%) patients had their catheters 
removed on day 1, in 23 (67.7%) patients catheter was 
removed on day 2, and 4 (12%) had their catheters removed 
on day 3. No patient was postoperatively catheterised 
beyond day 3, unless catheter had been removed and 
patient was re-catheterised because of retention. Three 
(9%) patients did not pass urine after removal of catheter, 
they required re-catheterisation. 
Other Characteristics
Dysuria was reported by 6 (18%) patients (Clavien Dindo 
Scale (CS) 0). Frequency (having to go to pass urine every 
< 2 hours) was seen in 24 (70.6%) patients (CS 0), urgency 
(without bacteriuria, not treated) was seen in 6 (18%) 
Akhtar and Raina
 Journal of Lasers in Medical Sciences  Volume 9, Number 4, Autumn 2018264
patients (CS 0), retention in 3 (9%) patients (CS 1), and 
gross haematuria in 2 (6%) patients (CS 1) (Table 3).
Postoperative Symptoms
An average drop in IPSS score (measured 30 days after 
discharge) of 8.7 was noted on follow-up (Range 5-13).
Total Admission Days
Mean admission duration was 3.5 days (range: 2-6 days). 
No patient stayed longer than 6 days postoperatively. 
Most (26, 82%) patients were admitted a day before 
surgery, or were already admitted (2, 6%) for evaluation 
and optimisation in view of comorbidities. Only 6 (12%) 
were admitted on the day of surgery, and the average 
admission stay was 2 days in this group.
Discussion
To the best of the author’s knowledge, this is the first case 
series published on Laser PVP using an XPS 180W from 
an Indian setup. 
Age
The average age of the patients in our study was 68.7 years. 
It compares favourably with the average age of 65.4 years 
in the GOLIATH Trial,13 of 70.7 years in the Bachmann 
et al14 study of 201 consecutive cases, and of 68.9 years in 
the paper by Hueber et al15 (cohort undergoing Laser PVP 
using XPS 180W). 
In our study, age was not found to be an independent risk 
factor for complications, which was also determined in 
the study by Peyronnet et al.16
Symptoms
The average IPSS score in our patients was 20 which is 
slightly lower than some contemporary studies. In the 
GOLIATH Trial13 the average IPSS score was 21.2 in the 
GreenLightTM group, in the series by Ben-Zvi et al17 the 
average IPSS score was 24.2 and in the study by Eken et 
al10 the average IPSS of patients who had Laser PVP with 
XPS 180W was 23.8. 
Antiplatelet Medications
Patients on acetylsalicylic acid (aspirin): In our study 14 
(41%) of patients were on aspirin. No patient required 
blood transfusion perioperatively in our study. Five out 
of 27 patients had their catheter in place on day 2 and 
required saline irrigation to keep their urine clear. All 
these 5 (100%) were on Aspirin perioperatively which 
could not be stopped because of comorbidities. Of the 
2 patients in our study who developed haematuria after 
catheter removal, requiring conservative treatment 
neither was on aspirin/clopidogrel. 
This compares well with the GOLIATH trial,13 where in 
28/134 patients (20.9%) were on aspirin perioperatively. 
In the study by West and Woo,18 24 (17.5%) of 137 
patients treated by XPS 180W were anticoagulated. In 
their study of 201 consecutive patients Bachmann et al14 
had 55/201 patients (27.4%) who were on aspirin. They 
did not report any specific complications to this patient 
group. 
Patients on Clopidogrel
A total of 11 out of 34 (32.5%) patients in our study were 
on clopidogrel at the time of surgery. No patient in this 
group required blood transfusions postoperatively. One 
out of 3 (33%) patients who developed postoperative 
retention was on clopidogrel and aspirin. This patient 
required catheterisation and bladder washes for treatment 
of the retention. 
PSA Level
The average PSA level of our patients was 2.51. In the 
GOLIATH trial13 the PSA was 2.7 in the cohort of patients 
who underwent XPS 180W. The PSA level in the study 
by Eken et al10 the PSA level was 2.79 in the patients 
undergoing the XPS 180W Laser PVP. 
Relationship of PSA Level to Complications
Our study did not show any statistically significant 




The impact of prostate size on surgical outcomes has been 
studied in previous papers. West and Woo18 concluded 
Table 3. A List of Adverse Events Based on Peyronnet et al16
Clavien Dindo 
Grade






Retention of urine postoperatively in 
patient with urinary catheter previously
1
Retention of urine postoperatively 














Acute renal failure 0
Haemorrhagic shock 0
4b Acute respiratory failure 0
5 Death 0
Abbreviation: AE, adverse event.
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that there was no increase in the complication rate with 
increasing prostate size. 
Hueber et al19 studied the impact of preoperative size of 
the prostate on safety and outcome of surgery. Median 
prostate size was 50 mL (n=387 patients) vs 108 mL 
(n=741 patients) in the groups prostate volume (PV) <80 
mL vs PV ≥80 mL respectively. Conversion to TURP was 
significantly higher in the ≥80 mL prostate group with 
a rate of 8.4% compared to 0.6% in the <80 mL prostate 
group (P<0.01). In this study, the average fibre usage was 
1.1/case in the <80 mL group, and 1.5/case in the >80 mL 
group. Duration of hospital stay was almost similar in the 
two groups (Tables 4 and 5).
Duration of Catheterisation
The average duration of catheterisation in our study 
was 1.91 days, or 40.17 hours. This compares favourably 
with the GOLIATH study13 in which the average catheter 
duration was 40.8 hours in 128 patients of the XPS-
180W arm. In the study by Hueber et al19 the catheterised 
duration was 26 hours in the patients who had PV <80 
mL and was 34 hours in the patients who had PV >80 
mL. In the study by Eken et al,10 the average catheterised 
duration was 17.8 hours for the patients who underwent 
the XPS-180W.
Blood Transfusions
There were no blood transfusions in any of our patients 
in this study. In the study by Hueber et al,19 no patient 
required a transfusion. Bachmann et al14 also reported no 
blood transfusions in their series of 201 patients. In the 
GOLIATH Trial,13 there was none in the XPS-180W arm.
Reduction in IPSS Score
The average fall in IPSS score in our study was 8.7 per case 
at 1 month follow-up. The 30 days mean IPSS score in our 
patient population was 11.35. Similar observations have 
been noted by Bachmann et al14 who noted a fall of 11.5 in 
his study at 1 month follow-up, with a mean IPSS score of 
8.1 and in the GOLIATH Trial13 where the average fall was 
9.3 in the XPS group at 3 weeks follow-up with a mean 
Table 4. Surgical Characteristics of Patients With Prostate Sizes >80 mL
Number Prostate Size (mL) Lasing Time (min) Energy Used (kJ) Fibres Used
1 130 75 400 1
2 162 130 800 2
3 87 48 320 1
4 100 55 350 1
5 84 50 300 1
6 113 59 370 1
7 100 52 280 1
8 115 48 300 1
Patients n=8 Average size = 111.3 mL Average lasing time = 64 min 
Average energy used = 390 kJ/
case
Average number of fibres = 1.12/
case
Table 5. Comparison of the 2 Groups in Our Study
Parameters Group Ia Group IIb P Valuec 
Prostate size average (mL) 40.4 111.3 0.07
Lasing time, average (min) 38.1 64.6 1.0
Energy used (kJ), average 229.4 390 0.98
Fibres used 1.0/case 1.12/case 0.16
a Prostate size <80 mL (n = 26). 
b Prostate size >80 mL (n = 8).
c There was no statistically significant difference between the two groups 
in our study (P<0.05 significant).







of hospital stay 
(days)
GOLIATH, 2014 134 2.7
Benejam-Gaul et al20, 2014 39 1.3
Hueber et al,19 2015 1196 1.0
Our study, 2013-2015 34 3.5
IPSS score of 11.9. Eken et al10 showed a drop in IPSS at 6 
months of 15.46 (2-24). 
High-Risk Patients
A total of 18 patients in our study were high surgical risk 
patients, defined as ASA class 3 or 4. The outcomes of 
those patients were comparable; there were no Clavien 
Dindo Class 4a, 4b, or 5 complications in these patients. 
The statistical analysis of the duration of stay and adverse 
effects of the patients based on ASA class failed to show 
any significant difference between the two groups, 
showing that XPS-180W was safe in the high-risk patients 
in our study. 
Total Admission Days
Average duration of admission in our study was 3.5 days, 
more than the average of 24 hours in the study of Hueber 
et al.19 It compares favourably with the patients enrolled 
in the XPS-180W arm of the GOLIATH Trial,13 with an 
average stay of 65.5 hours (2.7 days) (Table 6).
Akhtar and Raina
 Journal of Lasers in Medical Sciences  Volume 9, Number 4, Autumn 2018266
Limitations 
The limitations of this study were a small sample size and 
its non-randomised design. There was no comparison 
with TURP. The surgeons who participated in this 
study were proficient in 120W-HPS Green Light Laser 
techniques, and this study may not reflect a learning 
curve that may occur when the XPS-180W is introduced 
in a setting previously inexperienced with 120W-HPS. 
Conclusion
Our study shows that XPS-180W is a safe, efficacious 
method and that it can be used for the treatment of patients 
with LUTS due to BPH. It has also demonstrated efficacy 
in patients who are on antiplatelet medications even up to 
and during the surgery. Rates of haematuria, postoperative 
retention and blood transfusions were low. Our study also 
showed that XPS-180W can be potentially used in large 
prostates (>80 mL) hitherto not considered optimal cases 
for minimal access techniques. We had a total of 18 (53%) 
high surgical risk (ASA class 3,4) patients in our study, 
and there was no significant difference in outcome in this 
group using the XPS-180W when compared with the ASA 
class 2 patients, proving it to be safe. 
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